natgillin/translations-raw huggingface dataset:
Artemether/lumefantrine/efaviren z (20/120 mg tablet, 6 doses of 4 tablets each over 3 days/600mg once daily) 
Artemeter/lumefantrin/efavirenz (20/120 mg tableta, 6 doza od po 4 tablete, tijekom 3 dana/600 mg jedanput na dan
Breast-feeding should be discontinued during treatment with efavirenz. 
Tijekom terapije efavirenzom mora se prekinuti dojenje.
Lumefantrine: 
lumefantrin:
problems with coordination or balance - stomach pain, diarrhoea, feeling sick (nausea), vomiting - itching - tiredness - feeling anxious, feeling depressed 
pospanost, poteškoće s koordinacijom ili ravnotežom - bol u trbuhu, proljev, mučnina, povraćanje
No dose adjustment is necessary for any of these medicinal products. 
Nije potrebno prilagođavati dozu niti jednog od ovih lijekova.
Liver enzymes: Elevations of AST and ALT to greater than five times the upper limit of the normal range (ULN) were seen in 3% of 1,008 patients treated with 600 mg of efavirenz (5-8% after long-term treatment in study 006). 
više od pet puta iznad gornje granice normale opažene su u 3% od 1008 bolesnika liječenih efavirenzom u dozi od 600 mg (5-8% nakon dugotrajnog liječenja u studiji 006).
AUC: ↔ Cmax: ↑ 11% (↑ 3 to ↑19) 
AUC: ↔ Cmax: ↑ 11% (↑ 3 do ↑19)
Efavirenz can be re-initiated in patients interrupting therapy because of rash. 
Moguće je ponovno započeti liječenje efavirenzom u bolesnika koji su ga zbog osipa prekinuli.
AUC: ↔* (↓ 9 to ↑ 10) Cmax: ↑ 17%* (↑ 8 to ↑ 27) Cmin: ↓ 42%* (↓ 31 to ↓ 51) 
AUC: ↔* (↓ 9 do ↑ 10) Cmax: ↑ 17%* (↑ 8 do ↑ 27) Cmin: ↓ 42%* (↓ 31 do ↓ 51)
concentrations for at least 2 weeks (until stable concentrations are reached) is recommended when starting or stopping treatment with efavirenz. 
Kod uvođenja ili prekida liječenja efavirenzom, preporučuje se pažljivo pratiti koncentracije imunosupresiva tijekom najmanje 2 tjedna (dok se postignu stabilne koncentracije).
There have also been post-marketing reports of severe depression, death by suicide, delusions, psychosis-like behaviour and catatonia. 
Nakon stavljanja lijeka u promet prijavljivani su slučajevi jake depresije, samoubojstava, deluzija, psihotičnog ponašanja i katatonije.
This combination should be used with caution. 
Mora se nastaviti s primjenom odgovarajućih mjera opreza.
Co-administration of efavirenz with the fixed-combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil is not recommended, unless needed for dose adjustment (for example, with rifampicin). 
emtricitabin i tenofovirdizoproksil, osim ako nije potrebno zbog prilagodbe doze (na primjer, s rifampicinom).
AUC: ↑ 34% (↑ 18 to ↑ 53) Cmax: ↑ 49% (↑ 32 to ↑ 69) 
AUC: ↑ 34% (↑ 18 do ↑ 53) Cmax: ↑ 49% (↑ 32 do ↑ 69)
Atovaquone: 
Atovakvon:
Elevations of GGT to greater than five times ULN were observed in 4% of all patients treated with 600 mg of efavirenz and 1.5-2% of patients treated with control regimens (7% of efavirenz-treated patients and 3% of control-treated patients after long-term treatment). 
Porast vrijednosti gamaglutamiltransferaze (GGT) do više od pet puta iznad gornje granice normale zabilježen je u 4% svih bolesnika koji su primali efavirenz u dozi od 600 mg i u 1,5-2% bolesnika liječenih kontrolnim protokolom (nakon dugotrajnog liječenja u 7% ispitanika koji su primali efavirenz i u 3% ispitanika u kontrolnom protokolu).
Ethinyloestradiol + norgestimate / efavirenz (0.035 mg + 0.25 mg once daily/600 mg once daily) 
Etiniloestradiol + norgestimat / efavirenz (0,035 mg + 0,25 mg jedanput na dan/600 mg mg jedanput na dan)
Hydroxybupropion: 
Hidroksibupropion:
Integrase strand transfer inhibitor Raltegravir/efavirenz (400 mg single dose/ -) 
Inhibitori integraze Raltegravir/efavirenz (400 mg jednostruka doza/ -)
Immune system disorders Uncommon Hypersensitivity Metabolism and nutrition disorders common hypertriglyceridaemia* uncommon hypercholesterolaemia* 
Poremećaji metabolizma i prehrane često hipertrigliceridemija* manje često hiperkolesterolemija*
< 400 copies/ml 
< 400 kopija /ml
Common (affects 1 to 10 users in 100) 
Često (javljaju se u 1 do 10 na 100 korisnika)
Study ACTG 364 enrolled 196 patients who had been treated with NRTIs but not with PIs or NNRTIs. 
364 uključeno je 196 bolesnika koji su već primali NRTI-je, ali ne i inhibitore proteaze ili NNRTI-je.
The net effect of coadministration is not clear 
Neto učinak istodobne primjene nije razjašnjen.
Posaconazole/efavirenz (--/400 mg once daily) 
Posakonazol/efavirenz (--/400 mg jedanput na dan)
AUC: ↓ 31% (↓ 8 to ↓47) Cmin: ↓ 40% 
AUC: ↓ 31% (↓ 8 do ↓47) Cmin: ↓ 40%
In a drug interaction study, carbamazepine plasma concentrations were decreased when carbamazepine was co-administered with efavirenz (see section 4.5). 
U ispitivanju interakcija lijekova, istodobna primjena karbamazepina s efavirenzom snizila je koncentraciju karbamazepina u plazmi (vidjeti dio 4.5).
Hydroxyitraconazole: 
Hidroksi-itrakonazol:
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS EFAVIRENZ TEVA 600 mg FILM-COATED TABLET: BLISTER FOIL LABEL 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP EFAVIRENZ TEVA 600 mg FILMOM OBLOŽENA
Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first two weeks of initiating therapy with efavirenz. 
Osip se obično javlja u prva dva tjedna od početka liječenja efavirenzom u obliku blagih do umjerenih makulopapuloznih kožnih erupcija.
(400/100 mg twice daily/ 600 mg once daily) 
(400/100 mg dvaput na dan/ 600 mg jedanput na dan)
No dose adjustment is necessary for rifampicin, including 600 mg. 
Nije potrebno prilagođavati dozu rifampicina, uključujući i dozu od
- Bupropion (a medicine used to treat depression or to help you stop smoking): your doctor may need to change your dose of bupropion. 
- Bupropion (lijek za liječenje depresije ili za pomoć pri prestanku pušenja): liječnik će Vam možda trebati promijeniti dozu bupropiona.
Rare (affects 1 to 10 users in 10,000) 
Rijetko (javljaju se u 1 do 10 na 10 000 korisnika)
Lopinavir concentrations: similar to lopinavir/ritonavir 400/100 mg twice daily without efavirenz 
Koncentracije lopinavira: slično kao kod primjene lopinavira/ritonavira u dozi od 400/100 mg dvaput na dan bez efavirenza
- Each Efavirenz Teva film-coated tablet contains 600 mg of the active substance efavirenz. 
- Jedna Efavirenz Teva filmom obložena tableta sadrži 600 mg djelatne tvari efavirenz.
These metabolites are essentially inactive against HIV-1. 
Ovi metaboliti u pravilu nemaju učinak protiv
< 50 copies/ml 
< 50 kopija /ml
Malformations were observed in 3 of 20 foetuses/newborns from efavirenz-treated cynomolgus monkeys given doses resulting in plasma efavirenz concentrations similar to those seen in humans. 
Kod cinomolgus ženki majmuna koje su primale efavirenz zabilježene su malformacije u 3 od 20 fetusa/novorođenih majmuna pri koncentracijama u plazmi sličnim onima u ljudi.
Dose adjustments of calcium channel blockers should be guided by clinical response (refer to the Summary of Product Characteristics for the calcium channel blocker). 
Pri prilagodbi doze blokatora kalcijevih kanala treba se voditi kliničkim odgovorom (vidjeti
Efavirenz Teva contains efavirenz and may cause dizziness, impaired concentration, and drowsiness. 
Efavirenz Teva može prouzročiti omaglicu, smetnje koncentracije i pospanost.
If efavirenz is co-administered with voriconazole, the voriconazole maintenance dose must be increased to 400 mg every 12 hours and the efavirenz dose must be reduced by 50%, i.e. to 300 mg once daily. 
Kod istodobne primjene s vorikonazolom, doza održavanja vorikonazola mora se povećati na 400 mg svakih 12 sati, a doza efavirenza smanjiti za 50%, odnosno na dozu od 300 mg jedanput na dan.
No clinically significant pharmacokinetic interaction 
Nema klinički značajnih farmakokinetičkih interakcija
When treatment with voriconazole is stopped, the initial dose of efavirenz should be restored (see section 4.5). 
Nakon prestanka liječenja vorikonazolom, ponovo treba uvesti početnu dozu efavirenza (vidjeti dio
Administration of activated charcoal may be used to aid removal of unabsorbed efavirenz. 
Za lakše uklanjanje neapsorbiranog efavirenza, može se primijeniti aktivni ugljen.
Cmax: ↓ 17% (↓ 6 to ↓ 26) b Cmin: ↓ 50% (↓ 40 to ↓ 59) 
Cmax: ↓ 17% (↓ 6 do ↓ 26) b Cmin: ↓ 50% (↓ 40 do ↓ 59)
Rosuvastatin is largely excreted unchanged via the faeces, therefore interaction with efavirenz is not expected. 
Preporuke vezano za istodobnu primjenu s efavirenzom neizmijenjen putem stolice, pa se stoga ne očekuje interakcija s efavirenzom.
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to combination antiretroviral therapy (CART). 
konzumiranje alkohola, jaku imunosupresiju, povećani indeks tjelesne mase), prijavljeni su slučajevi osteonekroze osobito u bolesnika s uznapredovalom bolesti HIV-a i/ili u bolesnika na dugotrajnom liječenju kombiniranom antivirusnom terapijom.
The safety and efficacy of efavirenz has not been established in patients with significant underlying liver disorders. 
Sigurnost i djelotvornost efavirenza u bolesnika koji su već imali značajne poremećaje jetrene funkcije nisu utvrđeni.
The increased efavirenz concentrations observed following administration of efavirenz with food may lead to an increase in frequency of adverse reactions (see sections 4.4 and 5.2). 
Povišene koncentracije efavirenza nakon njegove primjene s hranom mogu povećati učestalost nuspojava (vidjeti dijelove 4.4 i 5.2).
Selective Serotonin Reuptake Inhibitors (SSRIs) Sertraline/efavirenz (50 mg once daily/600 mg once daily) 
Selektivni inhibitori ponovne pohrane serotonina (SSRI) Sertralin/efavirenz (50 mg jedanput na dan/600 mg
Reproductive system and breast disorders Uncommon Gynaecomastia 
Poremećaji reproduktivnog sustava i dojki manje često ginekomastija
Efavirenz Teva 600 mg film-coated tablets Efavirenz 
Efavirenz Teva 600 mg filmom obložene tablete efavirenz
(hallucinations), mania (mental condition characterised by episodes of overactivity, elation or irritability), paranoia, suicidal thoughts, catatonia (condition in which the patient is rendered motionless and speechless for a period) - whistling, ringing or other persistent noise in the ears - tremor (shaking) - flushing 
ushita ili razdražljivosti), paranoja, suicidalne misli, katatonija (stanje u kojem je bolesnik neko vrijeme nepomičan i ne govori)
How to store Efavirenz Teva 
Kako čuvati Efavirenz Teva
- nervousness, forgetfulness, confusion, fitting (seizures), abnormal thoughts - blurred vision - a feeling of spinning or tilting (vertigo) - pain in the abdomen (stomach) caused by inflammation of the pancreas - allergic reaction (hypersensitivity) that may cause severe skin reactions (erythema multiforme, 
- osjećaj da se sve okreće ili tlo naginje (vrtoglavica) - bol u trbuhu (želucu) prouzročena upalom gušterače - alergijska reakcija (preosjetljivost) koja može prouzročiti teške kožne reakcije (multiformni eritem, Stevens-Johnsonov sindrom)
Depomedroxyprogesterone acetate (DMPA)/efavirenz (150 mg IM single dose DMPA) 
Injekcija: Depomedroksiprogesteron acetat (DMPA)/efavirenz (150 mg IM jednostruka doza DMPA)
Each film-coated tablet contains 600 mg efavirenz. 
Jedna filmom obložena tableta sadrži 600 mg efavirenza.
Convulsions have been observed in adult and paediatric patients receiving efavirenz, generally in the presence of known medical history of seizures. 
U odraslih i pedijatrijskih bolesnika koji su uzimali efavirenz zabilježene su konvulzije i to obično u onih s napadajima u anamnezi.
- a history of symptomatic cardiac arrhythmias or with clinically relevant bradycardia or with congestive cardiac failure accompanied by reduced left ventricle ejection fraction. 
simptomatske srčane aritmije u anamnezi ili klinički značajnu bradikardiju ili kongestivno zatajenje srca praćeno smanjenjem ejekcijske frakcije lijeve klijetke. teške poremećaje ravnoteže elektrolita, npr. hipokalijemiju ili hipomagnezemiju.
At baseline, median plasma HIV-1 RNA was 4.57 log10 copies/mL, median CD4+ cell count was 755 cells/mm3, and median CD4+ percentage was 30%. 
Na početku ispitivanja je medijan HIV-1 RNK u plazmi iznosio 4,57 log10 kopija/ml, medijan broja CD4+ stanica iznosio je 755 stanica/mm3, a medijan postotka CD4+ iznosio je 30%.
Study 006, a randomized, open-label trial, compared efavirenz + zidovudine + lamivudine or efavirenz + indinavir with indinavir + zidovudine + lamivudine in 1,266 patients who were required to be efavirenz-, lamivudine-, NNRTI-, and PI-naive at study entry. 
zidovudin + lamivudin ili efavirenz + indinavir s kombinacijom indinavir + zidovudin + lamivudin u 1266 bolesnika koji prije ulaska u ispitivanje nisu primali efavirenz, lamivudin, NNRTI-je, niti inhibitore proteaze.
AUC: ↑ 21% (↑ 10 to ↑ 34) Cmax: ↑ 14% (↑ 4 to ↑ 26) Cmin: ↑ 25% (↑ 7 to ↑ 46) 
AUC: ↑ 21% (↑ 10 do ↑ 34) Cmax: ↑ 14% (↑ 4 do ↑ 26) Cmin: ↑ 25% (↑ 7 do ↑ 46) b
When efavirenz is co-administered with voriconazole, the voriconazole maintenance dose must be increased to 400 mg twice daily and the efavirenz dose must be reduced by 50%, i.e. to 300 mg once daily. 
s vorikonazolom, dozu održavanja vorikonazola treba povisiti na 400 mg dvaput na dan, dok se doza efavirenza mora sniziti za 50%, tj. na 300 mg jedanput na dan.
It is recommended that efavirenz be taken on an empty stomach, preferably at bedtime. 
Preporučuje se efavirenz uzimati na prazan želudac, najbolje prije spavanja.
Study PACTG 1021 was an open-label study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of efavirenz in combination with didanosine and emtricitabine in paediatric patients who were antiretroviral therapy naive. 
Ispitivanje PACTG 1021 bilo je otvoreno ispitivanje za procjenu farmakokinetike, sigurnosti, podnošljivosti i antivirusnog djelovanja efavirenza u kombinaciji s didanozinom i emtricitabinom u pedijatrijskih bolesnika koji prethodno nisu bili liječeni antiretrovirusnim lijekovima.
Desacetyl diltiazem: 
Dezacetil-diltiazem:
Plasma concentrations and effects of warfarin or acenocoumarol are potentially increased or decreased by efavirenz. 
Efavirenz može povećati ili smanjiti koncentracije u plazmi i učinke varfarina ili acenokumarola.
- unexplained feelings of distress not associated with hallucinations, but it may be difficult to think clearly or sensibly - suicide 
U većini slučajeva radi se o bolesnicima s već postojećom bolešću jetre, ali je nekoliko slučajeva zabilježeno i u bolesnika koji nisu imali bolest jetre. - neobjašnjivi osjećaj jada, koji nije povezan s halucinacijama, ali može biti teško jasno ili razumno razmišljati - samoubojstvo
In 35 patients receiving efavirenz 600 mg once daily, steady-state Cmax was 12.9 ± 3.7 microM (29%) [mean ± S.D. (% C.V.)], steady-state Cmin was 5.6 ± 3.2 microM (57%), and AUC was 184 ± 73 microM·h (40%). 
microM (29%) [srednja vrijednost ± S.D. (% C.V.)], Cmin 5,6 ± 3,2 microM (57%), a AUC 184 ± 73 microM·h (40%).
If therapy with efavirenz is discontinued, consideration should also be given to interrupting therapy with other antiretroviral agents to avoid development of resistant virus (see section 4.8). 
Ako se prekine liječenje efavirenzom, također treba razmotriti prekid liječenja drugim antiretrovirusnim lijekovima radi sprječavanja nastanka rezistentnog virusa
AUC: ↓ 83% (↓ 79 to ↓ 87) Cmax: ↓ 80% (↓ 77 to ↓ 83) Cmin: ↓ 86% (↓ 80 to ↓ 90) 
AUC: ↓ 83% (↓ 79 do ↓ 87) Cmax: ↓ 80% (↓ 77 do ↓ 83) Cmin: ↓ 86% (↓ 80 do ↓ 90)
Itraconazole: 
Itrakonazol:
ACID-REDUCING AGENTS Aluminium hydroxidemagnesium hydroxidesimethicone antacid/efavirenz (30 ml single dose/400 mg single dose) 
Aluminijev hidroksid-magnezijev hidroksid-simetikon antacid/efavirenz (30 ml jednostruka doza /400 mg jednostruka doza)
- Warfarin or acenocoumarol (medicines used to reduce clotting of the blood): your doctor may need to adjust your dose of warfarin or acenocoumarol. 
- Varfarin ili acenokumarol (lijek koji se koristi za smanjivanje zgrušavanja krvi): liječnik će
imidazole and triazole antifungal agents, - certain non-sedating antihistamines (terfenadine, astemizole), - cisapride, - flecainide, - certain antimalarials, - methadone. 
antimikotike koji sadrže imidazol i triazol, pojedine antihistaminike koji nemaju sedativno djelovanje (terfenadin, astemizol), cisaprid, flekainid, pojedine antimalarike i metadon (vidjeti dio 4.3).
Pregnancy, breast-feeding and fertility Women should not get pregnant during treatment with Efavirenz Teva and for 12 weeks thereafter. 
Žene ne smiju zatrudnjeti tijekom liječenja i 12 tjedana nakon završetka liječenja Efavirenzom Teva.
Grapefruit juice should be avoided when taking Efavirenz Teva. 
Za vrijeme uzimanja lijeka Efavirenz Teva treba izbjegavati sok od grejpa.
Medicinal product by therapeutic areas (dose) 
Lijekovi po terapijskim područjima
Famotidine/efavirenz (40 mg single dose/400 mg single dose) 
Famotidin/efavirenz (40 mg jednostruka doza /400 mg
Study AI266922 was an open-label study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of efavirenz in combination with didanosine and emtricitabine in antiretroviral-naive and -experienced paediatric patients. 
Ispitivanje AI266922 bilo je otvoreno ispitivanje za procjenu farmakokinetike, sigurnosti, podnošljivosti i antivirusnog djelovanja efavirenza u kombinaciji s didanozinom i emtricitabinom u pedijatrijskih bolesnika koji prethodno nisu bili liječeni i onih koji su već liječeni antiretrovirusnim lijekovima.
LIPID-LOWERING MEDICINAL PRODUCTS HMG CoA Reductase Inhibitors Atorvastatin/efavirenz (10 mg once daily/600 mg once daily) 
HIPOLIPEMICI Inhibitori HMG Co-A reduktaze Atorvastatin/efavirenz (10 mg jedanput na dan/600 mg jedanput na dan)
Efavirenz induced foetal resorptions in rats. 
Kod štakora je efavirenz inducirao resorpciju fetusa.
Study PACTG 382 was an open-label study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of efavirenz in combination with nelfinavir and an NRTI in antiretroviral-naive and NRTI-experienced paediatric patients. 
Ispitivanje PACTG 382 bilo je otvoreno ispitivanje za procjenu farmakokinetike, sigurnosti, podnošljivosti i antivirusnog djelovanja efavirenza u kombinaciji s nelfinavirom i NRTI-ma u pedijatrijskih bolesnika koji prethodno nisu bili liječeni antiretrovirusnim lijekovima i u onih koji su već liječeni NRTI-ma.
voriconazole. 
vorikonazol.
Tests may show: - increased liver enzymes in the blood - increased triglycerides (fatty acids) in the blood 
- svrbež - umor - osjećaj tjeskobe, depresivno raspoloženje Pretrage mogu pokazati: - povišene razine jetrenih enzima u krvi - povišene razine triglicerida (masnih kiselina) u krvi
ANTICOAGULANTS Warfarin/efavirenz Acenocoumarol/efavirenz 
Varfarin/efavirenz Acenokumarol/efavirenz
Theoretically, efavirenz may therefore initially increase the exposure to CYP3A4 substrates and caution is warranted for CYP3A4 substrates with narrow therapeutic index (see section 4.3). 
CYP3A4 pa je potreban oprez sa supstratima CYP3A4 uskog terapijskog indeksa (vidjeti dio 4.3).
Five of these NNRTI-resistant isolates were found to have K103N or a valine-to-isoleucine substitution at position 108 (V108I) in RT. Three of the efavirenz treatment failure isolates tested remained sensitive to efavirenz in cell culture and were also sensitive to nevirapine and delavirdine. 
U pet od tih izolata rezistentnih na NNRTI ustanovljena je zamjena K103N ili zamjena valina izoleucinom na mjestu 108 (V108I) u reverznoj transkriptazi.
Table 2: Efficacy results for study 006 Treatment regimen d n 
Tablica 2: Rezultati djelotvornosti iz ispitivanja 006 Terapijski protokol d n Stope bolesnika s odgovorom (NC = F a) HIV-RNK u plazmi
Hepatitis C antivirals Boceprevir/efavirenz (800 mg 3 times daily/600 mg 
Antivirusni lijekovi za hepatitis C Boceprevir/efavirenz (800 mg 3 puta na dan /600 mg jedanput na dan)
Common Abdominal pain, diarrhoea, nausea, vomiting Uncommon Pancreatitis 
Poremećaji probavnog sustava često bolovi u abdomenu, proljev, mučnina, povraćanje manje često pankreatitis
AUC12: ↓ 45% (↓ 38 to ↓ 51) Cmax: ↓ 51% (↓ 37 to ↓ 62) 
AUC12: ↓ 45% (↓ 38 do ↓ 51) Cmax: ↓ 51% (↓ 37 do ↓ 62)
No data are available to make a dose recommendation. 
Nisu provedena ispitivanja interakcija Nema dostupnih podataka da bi se mogla dati preporuka za dozu.
Voriconazole: 
Vorikonazol:
artemether/lumefantrine: Efavirenz Teva may reduce the amount of artemether/lumefantrine in your blood atovaquone/proguanil: Efavirenz Teva may reduce the amount of atovaquone/proguanil in your blood. 
artemeter/lumefantrin: Efavirenz Teva može smanjiti koncentraciju artemetera/lumefantrina u krvi.
Skin rash was considered treatment-related in 18% of patients treated with efavirenz. 
Smatra se da je u 18% bolesnika osip bio povezan s primjenom efavirenza.
Efavirenz must be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement or fever. 
Liječenje efavirenzom mora se prekinuti u bolesnika u kojih se razvije jaki osip s mjehurima, deskvamacijom,
Telaprevir/efavirenz (1,125 mg q8h/600 mg once daily) 
Telaprevir/efavirenz (1.125 mg q8h/600 mg jedanput na dan)
triazole antifungal agents certain antimalarial treatments methadone (used to treat opiate addiction) 
o lijekove za liječenje gljivičnih infekcija koji sadrže triazol o pojedine lijekove za liječenje malarije o metadon (za liječenje ovisnosti o opijatima).
Liver disease 
Oštećenje jetre
Velpatasvir/sofosbuvir/voxilap revir 
velpatasvir/sofosbuvir/voksilaprevir ↓velpatasvir
CARDIOVASCULAR AGENTS Calcium Channel Blockers Diltiazem/efavirenz (240 mg once daily/600 mg once daily) 
Blokatori kalcijevih kanala Diltiazem/efavirenz (240 mg jedanput na dan/600 mg jedanput na dan)
Plasma HIV-RNA 
HIV-1 virusa.
Multipack (bundle) containing 90 film-coated tablets (3 packs of 30 x 1 film-coated tablet) in white opaque PVC/PVdC-aluminium or aluminium-aluminium perforated unit-dose blisters. 
Višestruko pakiranje (paket) sa 90 filmom obloženih tableta (3 pakovanja sa 30 x 1 filmom obloženom tabletom) u bijelim, neprozirnim, PVC/PVdC-aluminijskim ili aluminij-aluminijskim perforiranim blisterima djeljivim na jedinične doze.
Clarithromycin/efavirenz (500 mg q12h/400 mg once daily) 
Klaritromicin/efavirenz (500 mg q12h/400 mg jedanput na dan)
AUC: ↓ 58% (↓ 39 to ↓ 68) Cmax: ↓ 51% (↓ 32 to ↓ 58) 
AUC: ↓ 58% (↓ 39 do ↓ 68) Cmax: ↓ 51% (↓ 32 do ↓ 58)
90 x 1 film-coated tablet in white opaque PVC/PVdC-aluminium perforated unit-dose blisters. 
90 x 1 filmom obloženih tableta u bijelim, neprozirnim PVC/PVdC-aluminijskim perforiranim blisterima djeljivim na jedinične doze.
Cmax: ↑ 11% (↑ 6 to ↑ 16) 
Cmax: ↑ 11% (↑ 6 do ↑ 16) Cmin: ↔
Indinavir/efavirenz (800 mg q8h/200 mg once daily) 
Indinavir/efavirenz (800 mg q8h/200 mg jedanput na dan)
AUC: ↓ 39% (↓ 21 to ↓ 53) Cmax: ↓ 37% (↓ 20 to ↓ 51) Cmin: ↓ 44% (↓ 27 to ↓ 58) 
AUC: ↓ 39% (↓ 21 do ↓ 53) Cmax: ↓ 37% (↓ 20 do ↓ 51) Cmin: ↓ 44% (↓ 27 do ↓ 58)
Dose adjustment of buprenorphine or efavirenz may not be necessary when co-administered. 
Pri istodobnoj primjeni možda neće biti potrebna prilagodba doze buprenorfina ili efavirenza.
Triacetin 3 
PRILOG III.
Atovaquone and proguanil hydrochloride/efavirenz (250/100 mg single dose/600 mg once daily) 
Atovakvon i progvanilklorid/efavirenz (250/100 mg jednostruka doza/600 mg jedanput na dan)
Patients with a prior history of psychiatric disorders appear to be at greater risk of these serious psychiatric adverse reactions. 
Čini se da je rizik od pojave ozbiljnih psihijatrijskih poremećaja veći u bolesnika s psihijatrijskim poremećajima u anamnezi.
Multipack (carton) containing 90 film-coated tablets (3 packs of 30 x 1 film-coated tablet) in white opaque PVC/PVdC-aluminium or aluminium-aluminium perforated unit-dose blisters. 
Višestruko pakiranje (kutija) sa 90 filmom obloženih tableta (3 pakovanja sa 30 x 1 filmom obloženom tabletom) u bijelim, neprozirnim, PVC/PVdC-aluminijskim ili aluminij-aluminijskim perforiranim blisterima djeljivim na jedinične doze.
AUC: ↓ 75% (↓ 62 to ↓ 84) Cmax: ↓ 44% (↓ 20 to ↓ 61) 
AUC: ↓ 75% (↓ 62 do ↓ 84) Cmax: ↓ 44% (↓ 20 to ↓ 61)